1 Title

2	Defining the Burden of Disease of RSV in Europe: estimates of RSV-associated
3	hospitalisations in children under 5 years of age. A systematic review and modelling study.
4	
5	Authors: Marco Del Riccio ¹ , Peter Spreeuwenberg ¹ , Richard Osei-Yeboah ³ , Caroline K.
6	Johannesen ⁴ , Liliana Vazquez Fernandez ⁵ , Anne C. Teirlinck ⁶ , Xin Wang ⁷ , Terho Heikkinen ⁸ ,
7	Mathieu Bangert ⁹ , Saverio Caini ¹ , Harry Campbell ³ , John Paget ¹ on behalf of the RESCEU
8	investigators
9	
10	Affiliations:
11	1. Netherlands Institute for Health Services Research (Nivel), Utrecht, The Netherlands
12	2. Department of Health Sciences, University of Florence, 50134 Florence, Italy
13	3. Centre for Global Health, Usher Institute, University of Edinburgh
14	4. Statens Serum Institut, Copenhagen, Denmark
15	5. Department of Methods Development & Analytics, Norwegian Institute of Public
16	Health, Oslo, Norway
17	6. Centre for Infectious Disease Control, National Institute for Public Health and the
18	Environment, Bilthoven, the Netherlands
19	7. School of Public Health, Nanjing Medical University, Nanjing, China
20	8. Department of Pediatrics, University of Turku and Turku University Hospital, Turku,
21	Finland
22	9. Sanofi Vaccines, Lyon, France
23	
24	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 Abstract

Background: Respiratory syncytial virus (RSV) infections cause an estimated 22-50 million
episodes of acute lower respiratory infections (ALRI) every year in children younger than 5
years. To date, no overall estimate of RSV-associated hospitalisations in children under 5 years
has been published for the European Union (EU). Through statistical modelling, we estimated
the RSV hospitalisation burden in children under 5 years of age in EU countries and Norway,
by age group and country.

Methods: We collated national RSV-associated hospitalisation estimates calculated using linear regression models in children under 5 years via the RESCEU project for Denmark, England, Finland, Norway, the Netherlands and Scotland during 2006-2018. A systematic literature review was conducted to collect additional estimates. Using the multiple imputation and nearest neighbour matching extrapolation methods, we estimated RSV-associated hospitalisation rates in all EU countries.

Results: Additional estimates for Spain and France were found in the literature and added to 38 39 the analysis. We estimated that an average of 245,244 (95%CI 224,688-265,799) hospital admissions with a respiratory infection per year were associated with RSV in children under 40 the age of 5, with most cases occurring among children aged less than 1 year (75%). Infants 41 42 aged less than 2 months represented the most affected group (71.6 per 1,000 children; 95% CI: 43 66.6-76.6). The hospitalisation rates varied widely across countries: for example, estimated 44 rates in the 0-2 months age group ranged from 47.4 (37.5-57.3) per 1,000 in the Netherlands to 45 98.3 (88.5-108.1) per 1,000 in France.

46 Conclusion: To our knowledge, this is the first attempt to estimate the overall RSV
47 hospitalisation burden in children under the age of 5 years in the EU. Our findings will help
48 support decisions regarding prevention efforts, and they will also represent an important

- 49 benchmark to understand changes in the RSV burden following the introduction of RSV
- 50 immunisation programs in Europe.
- 51
- 52 Keywords: Respiratory Syncytial Virus; Hospitalization; Burden of disease; Respiratory
- 53 Hospitalization; Europe; Modelling.
- 54

55 Introduction

It is globally estimated that respiratory syncytial virus (RSV) is associated with about 22% of 56 57 all acute lower respiratory infections (ALRI) [1] and this results in approximately 101,400 58 (84,500 – 125,200) deaths per year in young children [2]. Several studies have been conducted to understand the burden of RSV-associated infections, hospitalisations, and deaths in children 59 in Europe. For example, Reeves et al. explored routinely collected hospital data on RSV in 60 61 children aged <5 years in 7 European countries and compared these to RSV-associated admission rates [3], while Demont et al. provided information on the clinical and economic 62 63 burden of RSV-associated hospitalisation in children aged <5 years in France between 2010 64 and 2018 [4]. Despite these efforts, no estimates for RSV-associated hospitalisations are available for children in the EU as a whole. 65

66 RSV-associated hospitalisation estimates are important for public health purposes, as they can 67 help allocate resources, and provide important insights and inputs for prevention measures and strategies. The establishment of a robust age-specific burden of disease estimates, which have 68 69 often been limited due to a lack of routine testing for RSV [5], has also been underlined by the 70 World Health Organization (WHO) [6].

71 In this paper, we present overall and country-specific estimates of RSV-associated respiratory hospitalisations (absolute numbers and rates) by age group in children aged less than 5 years 72 73 in the 28 countries of the European Union (EU-28: includes the United Kingdom (UK) as it 74 was part of EU when the data were collected) and Norway. We then used these estimates to 75 calculate the proportion of RSV-associated hospitalisations among all-cause hospitalisations 76 and respiratory hospitalisations in this age group, for each country. Estimates of the hospital 77 burden of RSV are not available in many EU countries and our data will allow comparisons between countries and with other regions of the world, support efforts to communicate the RSV 78 79 disease burden, and provide important data for decisions regarding future prevention and

80 control measures linked to various immunisation programmes (such as vaccines and/or81 monoclonal antibodies).

82

83 Methods

84 Data sources

We searched for published and unpublished national estimates of RSV-associated hospitalisations (defined as any admission that contained at least one respiratory infectionspecific ICD-10 code at any point during admission) in children under 5 years in EU countries that were calculated using regression models as input data for the statistical analysis.

89

90 RSV-associated hospitalisation estimates from the RESCEU project

91 The data sources for Denmark, England, Finland, Norway, the Netherlands, and Scotland have 92 been described in papers that were previously published by the REspiratory Syncytial virus 93 Consortium in EUrope (RESCEU) [3]. Briefly, a retrospective study of overall respiratory 94 hospital admissions (i.e., respiratory tract infections with or without an associated pathogen), RSV-related respiratory admissions, and other pathogen-respiratory admissions in children <5 95 96 years of age using routinely collected hospital admissions databases was conducted in these 6 countries of the EU/European Economic Area (EEA). Age-specific estimates of RSV-97 associated hospitalisations in children during 2006-2018 were calculated for these countries by 98 99 using a linear regression approach [7], with estimates available for the following age groups: 100 0-2, 3-5, 6-11, 12-35, and 36-59 months.

101

102 Literature review estimates to identify estimates in other countries

103 In order to increase the geographical representativeness of this work, we searched the scientific

104 literature for additional data points in EU countries by adopting the same search strategy as a

previously published systematic review that aimed to estimate the global incidence, hospital admission rate, and mortality due to RSV in young children based on national estimates [2]. The systematic review by Li et al. was broader in scope and inclusion criteria (i.e., they included studies reporting incidence and in-hospital and out-of-hospital mortality, not only hospitalisation rates), therefore, we considered that the included records needed to be further screened and assessed for eligibility in our review.

111 The new search was conducted according to the Preferred Reporting Items for Systematic 112 Reviews and Meta-Analyses (PRISMA) statement [8]. The same search string as the systematic 113 review conducted by Li and colleagues was used [2] (see Supplementary material); MEDLINE and EMBASE databases were searched from 1st January 2019 to 30th November 2021 for 114 original articles. Papers published before 2019 that had been included by Li and colleagues 115 were added to the reference list of relevant papers and further assessed for eligibility. No 116 117 language restrictions were applied as long as an English abstract was available to decide on 118 eligibility. To be included, a study had to report (i) national estimates of RSV-associated 119 hospitalisations in children in EU countries calculated by using regression models (in order to 120 have a homogeneous pool of estimates) (ii) details (i.e., ICD codes) on the diagnosis (i.e., 121 bronchiolitis, lower respiratory infections, etc.), and (iii) analyse the same age bands used by 122 Johannesen and colleagues [7].

After removing duplicates, titles and abstracts were independently screened by two researchers (MDR and ROY) and the articles that were not excluded were retrieved in full copy and independently read by two authors (MDR and ROY). The papers that had been included in the previous systematic review were further assessed for eligibility, and the reference list of all eligible papers was checked by means of backward citation chaining for further relevant references. Data extraction was organised using an internally piloted spreadsheet [2]. The estimates reported by the included articles were then extracted and used as input data for the

statistical modelling, along with other information (data sources, details on the primary
diagnosis, years in which the study was conducted, etc.). The quality assessment of the included
studies was conducted by using a tool designed by Li et al. [2] (see Supplementary material).
Based on the assessment of different questions (on study testing, subjects, case definition,
sampling strategy, diagnostic tests, adjustment for health-care utilization) an overall score was
calculated.

136

137 Statistical Analysis

A two stage-modelling approach was used to estimate the respiratory hospitalisation burden of
RSV in children under 5 years old. This method was adapted from prior work focused on
influenza-associated mortality during the 2009 pandemic [9] and for seasonal influenza [10].
Since the period covered by the eligible studies was 2006-2018, the United Kingdom (UK) was
included in the EU estimates.

In Stage 1, we identified annual age-specific estimates of RSV-associated hospitalisations from
respiratory causes that were calculated using regression models. Data from the six RESCEU
countries, plus those which were found in the literature and matched the inclusion criteria (see
Results), were used as input data for Stage 2.

In Stage 2, we used the country estimates to extrapolate the hospitalisation burden and generate 147 148 plausible values for all EU countries and Norway using two different modelling approaches, 149 each involving two steps: (1) a data creation step using the matching approach or the multiple 150 imputation approach, and (2) a data analysis step where a hierarchical linear random effects model is used to project the burden in all EU countries. For both approaches, the data creation 151 152 step relied on 10 country-specific indicators representing health conditions at a demographic, geographic and population level (see Supplementary material) [9]. As two different sets of 10 153 154 indicators were used, the statistical modelling produced 4 sets of results (see Supplementary

155 material), each related to the combination of one set of indicators and one modelling approach. An average of the four different models was calculated and this was used to calculate the 156 157 absolute annual number and rates of RSV-associated hospitalisations (with uncertainty intervals) by country for the following age groups: 0-2, 3-5, 6-11, 12-35, and 36-59 months, 158 which are consistent with the previously published age groups used by Johannesen and 159 colleagues [7]. We also assessed the hospitalisations rate for EU28 in children aged 0-59 160 161 months and calculated the ratio of hospitalisations that occurred in each age group, considering our estimated total number of RSV-associated hospitalisations as denominator. 162

163 Finally, in order to compare RSV-associated hospitalisations to total respiratory and all-cause 164 hospitalisations, the estimated absolute number of RSV-associated hospitalisations was used as the numerator to calculate the proportion of RSV-associated hospitalisations among 165 166 respiratory and all-cause hospitalisations (data related to 2015) occurring in children under 5 years. The population denominator (roughly 25,900,000 children under 59 months of age in 167 EU28 in 2015) and other demographic indicators used for the analysis were obtained from 168 169 Eurostat [11]. Statistical analyses were conducted using Stata version 16 (Stata Corp, College 170 Station, TX).

171

172 **Results**

173 *Results of the literature review and Stage 1*

The literature search in MEDLINE and EMBASE produced 1,372 unique entries, and an additional 33 articles were found by backward citation chaining or because they had been included by Li and colleagues in the previous systematic review [2] (Figure 1). Of these, 1,304 were excluded based on title and abstract and 101 were read in full text: 99 were excluded for not matching the inclusion criteria; the main reason for exclusion was not presenting national RSV-associated hospitalisation estimates calculated by using regression methods. Two studies,

in particular, were excluded as they focused on different age groups [12-13] but they provided
useful estimates as they covered a country (England) that was included in Stage 1 (estimates
for England were already available) and were therefore comparable to the data reported by
Johannesen et al [7]. Finally, two studies [14-15] reporting RSV-associated hospitalisation
estimates for Spain from 1997 to 2011 and for France during 2010-2018 were included in the
review and their estimates were used as input data for the statistical modelling (Stage 2).

186 Both studies reported RSV-associated hospitalisation rates per 100,000 children in age groups that were slightly different to those used by Johannesen et al.; we therefore only used data 187 188 related to the age groups that were consistent with the estimates produced by Johannesen et al. 189 [7] (12-35 months and 36-59 months for Spain and 0-2 months, 3-5 months, and 6-11 months for France). Moreover, the estimates for France were not annual but based on the epidemic 190 191 periods only (October to March), so we recalculated the estimates for the whole year by 192 arbitrarily assuming little RSV activity during April-September (10% of the activity observed 193 from October to March [16]).

In total, data from 8 countries were used as Stage 1 inputs [(Denmark, England, Finland,
Norway, Netherlands, Scotland, France (age groups 0-2 months, 3-5 months, 6-11 months),
and Spain (age groups 12-35 months, 36-59 months)] (Table 1).

197

198 *Stage 2 estimates*

We included Stage 1 estimates from 8 countries in our analysis, roughly representing 40% of the population of the EU and Norway [17]. The results produced by the four models were consistent across the age groups, the highest rates being calculated with the multiple imputation approach and the lowest rates being calculated with the nearest neighbour matching approach (5% variation between the highest and lowest estimates of RSV hospitalisation rates in children

aged 0-2 months) (see Supplementary material). Here, we present the results for the average ofthe four models.

206 We estimated the average number and average annual rate (per 1,000 population) of RSV-207 associated hospitalisations by age group in different countries (Table 2 and Table 3). We estimated that an average of 245,244 (95%CI 224,688-265,799) hospital admissions with 208 209 respiratory infection were associated with RSV in the 28 EU countries per year in children 210 under the age of 5, with most cases occurring among children aged less than 1 year (74.9%)211 and those aged 1-2 years (20.7%) (Table 4). Infants aged less than 2 months represented the 212 most affected group (71.6 per 1,000 population; 95% CI: 66.6-76.6), with the rates declining as 213 the children got older: 38.9 per 1,000 in children aged 3-5 months, 17.6 (6-11 months), 5.0 (12-35 months) and 1.0 (36-59 months). Overall, we estimated that an average of 10 children per 214 1,000 living in the European Union are hospitalized due to RSV annually (average rates in 215 216 children 0-59 months: 10.06, 9.90-10.21 per 1,000 population).

We also estimated country-specific RSV-associated respiratory hospitalisations for each of the 29 countries and rates per 1,000 children (Table 2 and Table 3). The countries which had the highest absolute number of estimated hospitalisations were France (46,027 hospitalisations per year in children under 5 years), the UK (39,296 hospitalisations), and Germany (34,719 hospitalisations).

The hospitalisation rates varied widely across the EU: in the first age group (0-2 months) they ranged from 47.4 (95%CI: 37.6-57.3) per 1,000 population in the Netherlands to 98.3 (88.5-108.1) in France. The Netherlands presented the lowest rates in almost all the other age groups: 19.9 (14.5-25.4) per 1,000 population in children aged 3-5 months, 8.5 (5.7-11.3) in children aged 6-11 months, 1.9 (0.8-2.9) in children aged 12-35 months. The lowest rates for the age group 36-59 months were estimated for Norway (0.5, 95%CI 0.3-0.7). In the age group 0-5

years (0-59 months), the rates ranged from 8.61 (8.31-8.92) in Norway to 10.58 (10.30-18.86)
in Spain.

Most RSV-associated hospitalisations occurred in children aged less than 1 year (74.9% averaged, ranging from 65.4% in Denmark to 80.7% in Spain (Table 4)). The youngest group (0-2 months) was the most affected, with percentages ranging from 27.5% in Denmark to 43.8% in the Netherlands. RSV-associated hospitalisations were less likely in children aged from 3 to 4 years (36-59 months), with the percentage ranging from 3.3% in Finland to 8.4% in the Netherlands.

236

237 Comparison with total pediatric hospitalisations and respiratory pediatric hospitalisations

We compared the country estimates to total national paediatric hospitalisations and respiratory paediatric hospitalisations in the EU and Norway and found that RSV-associated hospitalisations represented from 1.8% (95%CI: 1.5-2.1; Lithuania) to 9.9 (95%CI: 8.4-11.5; Finland) of total hospitalisations in children younger than 5 years (Table 5) [11]. This percentage was higher for paediatric respiratory hospitalisations, ranging from 6.8% in Lithuania to 51.6% in Sweden, and these percentages are likely to be much higher during the winter, especially during the weeks when RSV circulates.

245

246 Discussion

Understanding the burden of disease caused by RSV, and specifically the incidence of hospitalisations and deaths, will help understand the impact of RSV prevention programs (new monoclonal antibodies and vaccines [18-21]). Our study estimated that an average of roughly 250,000 respiratory hospitalisations in children younger than 5 years were associated with RSV each year in the 28 EU countries included in the analysis, with 3 out of 4 hospitalisations (ranging from 65.4% in Denmark to 80.7% Spain) occurring on average in children aged 0-11

months and 96% in those aged less than 0-23 months (ranging from 93.9% in Portugal to 97.7%
in Norway) (Table 4).

255 We applied four extrapolation methods to obtain these estimates and saw no large differences 256 across the outcomes: this was reassuring as it suggests that our results are not driven by the choice of a specific model. Consistently with previous studies, our results show an increase in 257 RSV hospital admissions with a decrease in patient age, with infants under 1 year having the 258 259 highest burden of RSV hospitalisations (especially those aged 0-2 months of age) [22]. Demont and colleagues reported a similar percentage (70%) of hospitalisations associated with RSV 260 261 occurred in children <1 year [4] compared to our estimate for France (79%) and the EU-28 262 (75%; Table 4). Glatman-Freedman et al. (Israel), Saravanos et al. (Australia) and Arriola et al. (United States) have also found the highest age-specific hospitalisation rates in children 263 264 aged 0-2 months, with reductions in the other age groups [23-25]. This confirms how RSV 265 immunisation programmes targeting the first 6 months of life could be highly effective in 266 reducing most of the RSV hospitalisation burden [2].

267 Our estimates (and specifically the hospitalisation rates) varied strongly across the different EU countries, with the Netherlands having the lowest rates in almost all age groups (Norway 268 269 has the lowest rates in the age group 3-4 years) and France having the highest rates, with the highest relative difference observed in the age group 12-35 months (the estimated rate for 270 271 France was 5 times higher than the Netherlands). This finding is not entirely surprising as these 272 results reflect the Stage 1 data inputs that were entered into the Stage 2 modelling procedure, 273 where the Netherlands had the lowest [7] and France the highest rates [15]. Differences in the 274 outcome coding and in the study design (the French study was conducted during the winter 275 season, and we, therefore, needed to recalculate the estimates for a whole year) may explain 276 the higher rates reported in France. From a methodological perspective, these results highlight

the importance of having Stage 1 estimates that are calculated in a harmonized manner as theStage 2 extrapolations are sensitive to the Stage 1 inputs [26].

279 Whilst it is important to properly understand the real burden of disease associated with RSV in 280 Europe and to estimate the potential impact of prevention efforts, it is not easy to compare our country-specific results with findings from the literature, considering the use of other methods 281 to calculate these rates and the paucity of published studies. The recent, large perspective study 282 283 by Wildenbeest and colleagues [27], conducted in 5 European countries, reported lower but comparable hospitalisation rates (1.8% RSV-associated hospitalisation in the first year of life 284 285 in healthy term-born infants, 3.3% in children <3 months). The lower rates reported by 286 Wildenbeest and colleagues might be related to the exclusion of pre-term infants or those at highest risk for severe illness [28] which were included in the studies used in our analysis [7, 287 288 14-15]. Sanchez-Luna and colleagues reported between 5,997 (2005) and 8,637 (2012) hospital 289 discharges for RSV bronchiolitis (ICD-9 code 466.11 as the principal diagnosis) in Spain in 290 children aged under 1 year during 2004-2012 [28]. Our estimated number of average 291 admissions per year for Spain in this age group was 14,446 (95%CI 12,228-16,662) and this 292 reflects our hospitalisation estimate not being restricted to bronchiolitis, but all respiratory 293 hospitalisations. Moreover, as reported for England by Green et al. [29], there is an observed 294 general increase in RSV-associated admissions over the years that may be due to changes in 295 healthcare policies (an increase in hospital bed availability or a change in the admission 296 threshold) and this may explain the higher number of hospitalisations estimated by our study 297 for Spain. Our study also shows how hospitalisations due to RSV in children under 5 years 298 represent one of the leading causes of EU infant hospitalisations (Table 5): based on our 299 estimates, up to 1 in 10 hospitalized children under 5 years of age may be associated to RSV, 300 and this number is larger (around 4 out of 10 children in Italy, Portugal, Denmark and Finland, 301 1 out of 2 in Sweden) if we only consider respiratory hospitalisations (Table 5). Accurate and

reliable patient-based data on hospitalisations for multiple pathogens in children under 5 years
and the related cause(s) of the hospitalisation will be fundamental in assessing whether RSV is
actually the leading cause of infant hospitalisations in Europe, as recently demonstrated for the
United States [30].

Our study has a number of limitations: first, our extrapolations would benefit from more 306 countries with RSV-associated estimates to populate the statistical models (e.g., additional 307 308 country estimates in southern and eastern Europe); moreover, estimates based on prospectively collected data are needed to produce more reliable results (see Supplementary material). A 309 310 second limitation is that the estimates used for Stage 1 are regression-based and this holds 311 inherent uncertainties related to country-specific collection methods of laboratory data and ICD codes for hospital admissions (ICD-10 for all countries included except the study conducted in 312 313 Spain, in which ICD-9-CM was used) [31]. Without uniform reporting systems and consistent 314 coding practices, it is hard to generalize results to other countries. Despite this, whilst differences in coding can be profound when looking at a single code, they are reduced when 315 316 the modelling builds on a wider range of codes (e.g., all respiratory codes, as done by 317 Johannesen and colleagues [7]), as clinical practices and coding guidelines are less affected. Another limitation is that our estimates are based on country-specific hospitalisation rates that 318 319 were calculated for different time periods (see Table 1), thus possibly influenced by differences 320 in RSV circulation (e.g. types) over the years. Our study found substantial variation in the 321 hospitalisation rates across Europe, but we did not explore these differences as this would 322 require more advanced analysis methods which would include factors such as the circulation 323 of other respiratory viruses (e.g., influenza and SARS-CoV-2), healthcare (indicators related 324 to access and quality of healthcare or differences in the clinical practice), climatic and 325 environmental factors [32-33]. We also used two sets of ten indicators to produce the 326 extrapolations (see Supplementary material): these sets were chosen based on the availability

327 of data in all included countries (e.g., Scotland and England for the UK) and are not always specific to RSV. From a statistical perspective, this point is not likely to influence the estimates 328 329 (as the indicators only aim to capture variability across countries), but it would be more elegant 330 to develop indicator sets that are better aligned with RSV, as was done for influenza [9]. For example, the inclusion of indoor and outdoor pollution, which was reported by Nenna and 331 colleagues as a risk factor for acute bronchiolitis in infants aged less than 3 years old [34], or 332 333 the rates of premature birth, average maternal age, and delayed infant vaccinations, reported by Hardelid and co-authors as risk factors associated with increased RSV hospitalisations, 334 335 could be considered [35]). Finally, our extrapolations are based on a period in which COVID-336 19 was not present: it would be preferable to have more recent estimates to understand the impact of the COVID-19 pandemic on RSV circulation [36] and its burden in terms of 337 338 infections, hospitalisations, and deaths.

339 Despite these limitations, our study is, to our knowledge, the first attempt to estimate the RSV hospitalisation burden in children under the age of 5 years across Europe, and in EU countries 340 341 for which no estimates have been produced so far. These estimates should help optimize public health responses (e.g., the allocation of more resources to pediatric hospitals during the winter 342 343 season) and support planning for future immunisation programs [37]. Moreover, they represent 344 a benchmark to understand to understand changes in the RSV burden after the COVID-19 pandemic and in the future following the introduction of RSV immunisation programs in 345 346 Europe.

347

348 Study group members

349 The RESCEU investigators are as follows:

350 Harish NAIR (University of Edinburgh), Harry CAMPBELL (University of Edinburgh),

351 Philippe Beutels (Universiteit Antwerpen), Louis Bont (University Medical Center Utrecht),

352 Andrew Pollard (University of Oxford), Peter Openshaw (Imperial College London), Federico Martinon-Torres (Servicio Galego de Saude), Terho Heikkinen (University of Turku and Turku 353 University Hospital), Adam Meijer (National Institute for Public Health and the Environment), 354 355 Thea K. Fischer (Statens Serum Institut), Maarten van den Berge (University of Groningen), Carlo Giaquinto (PENTA Foundation), Michael Abram (AstraZeneca), Kena Swanson 356 (Pfizer), Bishoy Rizkalla (GlaxoSmithKline), Charlotte Vernhes (Sanofi Pasteur), Scott 357 358 Gallichan (Sanofi Pasteur), Jeroen Aerssens (Janssen), Veena Kumar (Novavax), Eva Molero 359 (Team-It Research)

360

361 Financial support

This work is part of RESCEU. RESCEU has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116019. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. This publication only reflects the author's view, and the JU is not responsible for any use that may be made of the information it contains herein.

367

368 Disclaimer

369 Data from the Norwegian Patient Registry have been used in this publication. The 370 interpretation and reporting of these data are the sole responsibility of the authors, and no 371 endorsement by the Norwegian Patient Registry is intended nor should be inferred. This work 372 reflects only the author's views and opinions. The EC is not responsible for any use that may 373 be made of the information it contains.

374

375 Potential conflicts of interest

16

- 376 HC reports grants, personal fees, and nonfinancial support from World Health Organization.
- 377 Grants and personal fees from Sanofi Pasteur. Grants from Bill and Melinda Gates Foundation.
- 378 All payments were made via the University of Edinburgh. HC is a shareholder in the Journal
- of Global Health Ltd. JP declares that Nivel has received unrestricted research grants regarding
- the epidemiology of RSV from Sanofi Pasteur and IMI in the past 12 months.

381 Table 1. Description of the data sources that provided Stage 1 estimates

Author, year	Country	Period of observation	Age groups	Age groups whose estimates were used as inputs	Outcome coding
Johannesen, 2022 [7]	Denmark	2010-2017	0-2m, 3-5m, 6-11m, 12-35m, 36-59m	0-2m, 3-5m, 6- 11m, 12-35m, 36- 59m	ICD-10; J00, J02-06 acute upper respiratory tract infection (URTI); J09-18 Pneumonia & influenza; J20-21, J40 Bronchiolitis and bronchitis; J22 Unspecified LRTI
Johannesen, 2022 [7]	England	2007-2017	0-2m, 3-5m, 6-11m, 12-35m, 36-59m	0-2m, 3-5m, 6- 11m, 12-35m, 36- 59m	ICD-10; J00, J02-06 acute upper respiratory tract infection (URTI); J09-18 Pneumonia & influenza; J20-21, J40 Bronchiolitis and bronchitis; J22 Unspecified LRTI
Johannesen, 2022 [7]	Finland	2006-2016	0-2m, 3-5m, 6-11m, 12-35m, 36-59m	0-2m, 3-5m, 6- 11m, 12-35m, 36- 59m	ICD-10; J00, J02-06 acute upper respiratory tract infection (URTI); J09-18 Pneumonia & influenza; J20-21, J40 Bronchiolitis and bronchitis; J22 Unspecified LRTI
Johannesen, 2022 [7]	Netherlands	2013-2017	0-2m, 3-5m, 6-11m, 12-35m, 36-59m	0-2m, 3-5m, 6- 11m, 12-35m, 36- 59m	ICD-10; J00, J02-06 acute upper respiratory tract infection (URTI); J09-18 Pneumonia & influenza; J20-21, J40 Bronchiolitis and bronchitis; J22 Unspecified LRTI
Johannesen, 2022 [7]	Norway	2008-2017	0-2m, 3-5m, 6-11m, 12-35m, 36-59m	0-2m, 3-5m, 6- 11m, 12-35m, 36- 59m	ICD-10; J00, J02-06 acute upper respiratory tract infection (URTI); J09-18 Pneumonia & influenza; J20-21, J40 Bronchiolitis and bronchitis; J22 Unspecified LRTI
Johannesen, 2022 [7]	Scotland	2010-2016	0-2m, 3-5m, 6-11m, 12-35m, 36-59m	0-2m, 3-5m, 6- 11m, 12-35m, 36- 59m	ICD-10; J00, J02-06 acute upper respiratory tract infection (URTI); J09-18 Pneumonia & influenza; J20-21, J40 Bronchiolitis and bronchitis; J22 Unspecified LRTI
Demont, 2020 [15]	France	2010-2018	0-2m, 3-5m, 6-11m, 12-23m, 24-59m	0-2m, 3-5m, 6-11m	ICD-10; J121, J205, J210, J219
Gil-Prieto, 2015 [14]	Spain	1997-2011	0y, 1y, 2y, 3y, 4y, <5y, <2y	2y, 3y, 4y	ICD-9-CM; 466, acute bronchitis and bronchiolitis; 480.1, pneumonia due to RSV; 079.6, RSV infection

Country	0-2 months (95%CI) ^a	3-5 months (95%CI) ^a	6-11 months (95%CI) ^a	12-35 months (95%CI) ^b	36-59 months (95%CI) ^b
EU28 ^c	71.6 (66.6-76.6)	38.9 (36-41.9)	17.6 (16.1-19.1)	5 (4.4-5.5)	1 (0.9-1.1)
Austria	65 (55.2-74.8)	33.1 (27.7-38.5)	13.5 (10.7-16.4)	4.5 (3.5-5.5)	0.9 (0.7-1.1)
Belgium	68.6 (58.8-78.4)	36.3 (30.9-41.7)	15.9 (13.1-18.7)	4.8 (3.8-5.9)	1.2 (0.9-1.4)
Bulgaria	81.8 (72-91.6)	48.9 (43.5-54.3)	21.2 (18.4-24)	5.5 (4.5-6.6)	1 (0.8-1.2)
Croatia	79.4 (69.7-89.2)	42.6 (37.2-48)	19 (16.2-21.8)	4.8 (3.8-5.8)	0.9 (0.7-1.1)
Cyprus	78.4 (68.6-88.2)	41.3 (35.9-46.7)	16.7 (13.9-19.5)	5.5 (4.5-6.5)	0.9 (0.7-1.1)
Czech Republic	73.9 (64.1-83.7)	41 (35.6-46.4)	18.4 (15.6-21.2)	5.7 (4.6-6.7)	1.1 (0.9-1.3)
Denmark	59.2 (49.3-69)	40.7 (35.3-46.2)	20.4 (17.5-23.2)	7.5 (6.4-8.5)	1.6 (1.4-1.8)
Estonia	69.8 (60-79.7)	37.3 (31.8-42.7)	17.2 (14.4-20.1)	5.1 (4-6.1)	1 (0.8-1.2)
Finland	77.8 (67.9-87.7)	43.2 (37.7-48.6)	16.6 (13.8-19.4)	5.2 (4.2-6.3)	0.8 (0.6-1)
France	98.3 (88.5-108.1)	48.8 (43.4-54.2)	26 (23.2-28.8)	5 (4-6.1)	1.1 (0.9-1.3)
Germany	72.5 (62.7-82.2)	38.6 (33.2-44)	17.5 (14.6-20.3)	5.2 (4.2-6.3)	1 (0.8-1.2)
Greece	82.6 (72.8-92.4)	44.3 (38.9-49.7)	19.1 (16.3-21.9)	4.5 (3.4-5.5)	0.9 (0.7-1.1)
Hungary	75.3 (65.5-85.1)	44.7 (39.3-50.1)	19.8 (16.9-22.6)	5.4 (4.4-6.4)	1.1 (0.9-1.3)
Ireland	70.1 (60.3-79.9)	47 (41.6-52.4)	22.6 (19.8-25.4)	7.1 (6-8.1)	1.3 (1-1.5)
Italy	80.9 (71.1-90.7)	41.7 (36.3-47.1)	18.1 (15.3-20.9)	4.3 (3.2-5.3)	0.9 (0.7-1.1)

382Table 2: Average RSV-associated hospitalisation rates per 1,000 population per age group per year

	•				
Latvia	75 (65.2-84.8)	41.3 (35.9-46.7)	18.4 (15.6-21.2)	4.6 (3.6-5.7)	1.1 (0.8-1.3)
Lithuania	73.6 (63.8-83.4)	38.5 (33.1-43.9)	17 (14.2-19.8)	4 (3-5)	0.9 (0.7-1.1)
Luxembourg	63.5 (53.7-73.3)	32.6 (27.2-38)	13.1 (10.3-15.9)	5 (4-6.1)	0.9 (0.7-1.1)
Malta	64.8 (54.8-74.7)	35.2 (29.7-40.7)	17.9 (15-20.7)	5.4 (4.4-6.5)	1.3 (1.1-1.5)
Netherlands	47.4 (37.6-57.3)	19.9 (14.5-25.4)	8.5 (5.7-11.3)	1.9 (0.8-2.9)	1.1 (0.9-1.3)
Norway	54.6 (44.5-64.7)	34.8 (29.3-40.3)	15.4 (12.5-18.2)	6.6 (5.6-7.7)	0.5 (0.3-0.7)
Poland	71.4 (61.6-81.2)	36.5 (31.1-41.9)	16.2 (13.4-19.1)	4.6 (3.5-5.6)	0.9 (0.7-1.1)
Portugal	70.2 (60.4-80)	31.7 (26.3-37.1)	15.2 (12.4-18)	4.5 (3.4-5.5)	1.2 (0.9-1.4)
Romania	68.8 (59-78.6)	37.7 (32.3-43.1)	19.4 (16.6-22.2)	4.1 (3.1-5.2)	1 (0.8-1.2)
Slovakia	74.6 (64.8-84.3)	42 (36.6-47.4)	18.8 (16-21.6)	4.7 (3.7-5.8)	0.8 (0.6-1)
Slovenia	75.4 (65.6-85.2)	42.6 (37.2-48)	17.6 (14.8-20.4)	5.2 (4.2-6.2)	1.1 (0.9-1.3)
Spain	69.4 (59.6-79.2)	32.6 (27.2-38)	16.8 (14-19.6)	3 (2-4.1)	0.8 (0.6-1)
Sweden	63 (53.1-72.8)	35.5 (30.1-41)	16.9 (14.1-19.7)	5.3 (4.3-6.3)	1.2 (1-1.4)
United Kingdom	63.4 (47.8-79.1)	38.9 (29.7-48.1)	18.9 (14.2-23.6)	6.1 (4.4-7.9)	1.3 (1-1.6)

383

^a RSV-associated hospitalisation rates in these three age groups for the 29 countries are estimated by also including data from France reported by Demont and

384 colleagues [15]

385 ^bRSV-associated hospitalisation rates in these two age groups for the 29 countries are estimated by also including data from Spain reported by Gil-Prieto and colleagues

386 [14]

387 ^c Includes the UK and excludes Norway

Country	0-2 months (95%CI) ^a	3-5 months (95%CI) ^a	6-11 months (95%CI) ^a	12-35 months (95%CI) ^b	36-59 months (95%CI) ^b
EU28 ^c	90,200 (83,923-96,476)	49,052 (45,328-52,776)	44,369 (40,529-48,208)	50,852 (45,249-56,456)	10,771 (9,659-11,883)
Austria	1,308 (1,111-1,505)	667 (558-775)	545 (432-658)	732 (563-902)	147 (112-182)
Belgium	2,141 (1,836-2,446)	1,133 (965-1,302)	992 (816-1,167)	1,235 (973-1,497)	306 (250-362)
Bulgaria	1,374 (1,210-1,539)	822 (732-913)	714 (620-808)	733 (596-869)	141 (112-171)
Croatia	783 (687-880)	420 (366-473)	375 (320-431)	391 (306-477)	77 (59-95)
Cyprus	181 (159-204)	95 (83-108)	77 (64-90)	106 (86-126)	18 (13-22)
Czech Republic	2,031 (1,762-2,300)	1,128 (979-1,276)	1,012 (858-1,167)	1,237 (1,012-1,462)	258 (209-308)
Denmark	846 (704-986)	582 (504-660)	582 (500-662)	864 (744-985)	199 (172-225)
Estonia	238 (205-271)	127 (108-146)	118 (98-137)	141 (112-170)	32 (25-38)
Finland	1,122 (980-1,264)	622 (544-701)	479 (398-561)	625 (501-750)	97 (71-124)
France	18,145 (16,336-19,952)	9,018 (8,021-10,015)	9,587 (8,548-10,626)	7,573 (5,998-9,148)	1,704 (1,368-2,040)
Germany	12,977 (11,223-14,731)	6,906 (5,939-7,874)	6,252 (5,244-7,260)	7,250 (5,802-8,699)	1,334 (1,039-1,629)
Greece	1,895 (1,670-2,119)	1,015 (891-1,139)	875 (746-1,003)	862 (661-1,063)	193 (147-239)
Hungary	1,748 (1,521-1,975)	1,038 (913-1,163)	917 (787-1,048)	976 (788-1,164)	199 (161-237)
Ireland	1,139 (980-1,298)	764 (676-851)	735 (643-826)	950 (810-1,091)	176 (146-206)
Italy	10,111 (8,888-11,334)	5,213 (4,538-5,888)	4,534 (3,832-5,236)	4,475 (3,387-5,563)	1,021 (787-1,256)

388	Table 3: Average RSV-ass	ociated hospitalisations	per age group per year
-----	--------------------------	--------------------------	------------------------

•					
Latvia	407 (353-459)	224 (195-253)	200 (169-230)	190 (148-232)	40 (32-48)
Lithuania	559 (485-633)	292 (251-333)	258 (215-300)	241 (179-304)	54 (42-67)
Luxembourg	96 (82-111)	49 (41-58)	40 (31-49)	64 (51-77)	12 (9-15)
Malta	69 (59-80)	38 (32-44)	38 (32-44)	47 (38-57)	11 (9-13)
Netherlands	2,071 (1,641-2,502)	870 (633-1,108)	741 (494-988)	651 (292-1,011)	398 (319-475)
Norway	811 (661-961)	517 (435-599)	456 (370-542)	812 (682-941)	61 (34-89)
Poland	6,542 (5,646-7,439)	3,346 (2,852-3,842)	2,979 (2,464-3,494)	3,459 (2,669-4,249)	730 (557-903)
Portugal	1,444 (1,243-1,645)	651 (540-762)	627 (511-742)	769 (590-949)	226 (185-268)
Romania	3,300 (2,830-3,769)	1,807 (1,548-2,066)	1,860 (1,590-2,129)	1,540 (1,150-1,929)	389 (305-472)
Slovakia	1,035 (900-1,170)	583 (509-658)	523 (445-600)	531 (414-648)	98 (72-123)
Slovenia	399 (347-451)	225 (197-254)	186 (156-216)	225 (180-270)	48 (38-57)
Spain	7,399 (6,356-8,442)	3,473 (2,897-4,048)	3,574 (2,975-4,172)	2,670 (1,762-3,578)	788 (585-992)
Sweden	1,824 (1,538-2,110)	1,030 (872-1,187)	980 (816-1,144)	1,229 (987-1,471)	288 (237-339)
United Kingdom	12,333 (9,291-15,375)	7,565 (5,778-9,351)	7,352 (5,515-9,188)	9,890 (7,128-12,652)	2,156 (1,614-2,698)

389 ^a RSV-associated hospitalisation in these three age groups are estimated by also including data from France reported by Demont and colleagues [15]

390 ^bRSV-associated hospitalisation in these two age groups are estimated by also including data from Spain reported by Gil-Prieto and colleagues [14]

391 ^c Includes the UK and excludes Norway

Country	0-2 months ^a - %	3-5 months ^a - %	6-11 months ^a - %	0-11 months ^{a,b} - %	12-35 months ^c - %	36-59 months ^c - %
EU28 ^d	36.8%	20.0%	18.1%	74.9	20.7	4.4
Austria	38.5%	19.6%	16.0%	74.1	21.6	4.3
Belgium	36.9%	19.5%	17.1%	73.4	21.3	5.3
Bulgaria	36.3%	21.7%	18.9%	76.9	19.4	3.7
Croatia	38.3%	20.5%	18.3%	77.1	19.1	3.8
Cyprus	37.9%	19.9%	16.1%	74.0	22.2	3.8
Czech Republic	35.8%	19.9%	17.9%	73.6	21.8	4.6
Denmark	27.5%	18.9%	18.9%	65.4	28.1	6.5
Estonia	36.3%	19.4%	18.0%	73.6	21.5	4.9
Finland	38.1%	21.1%	16.3%	75.5	21.2	3.3
France	39.4%	19.6%	20.8%	79.8	16.5	3.7
Germany	37.4%	19.9%	18.0%	75.3	20.9	3.8
Greece	39.2%	21.0%	18.1%	78.2	17.8	4.0
Hungary	35.8%	21.3%	18.8%	75.9	20.0	4.1
Ireland	30.3%	20.3%	19.5%	70.1	25.2	4.7

Table 4: Ratio of RSV-associated hospitalisation occurring in children aged less than 1 year, from 1 to 2 years and from 3 to 4 years (100% is

represented by all RSV-associated hospitalisation occurring in children under 5 years).

392

Italy	39.9%	20.6%	17.9%	78.3	17.7	4.0
Latvia	38.4%	21.1%	18.9%	78.3	17.9	3.8
Lithuania	39.8%	20.8%	18.4%	79.0	17.2	3.8
Luxembourg	36.8%	18.8%	15.3%	70.9	24.5	4.6
Malta	34.0%	18.7%	18.7%	71.4	23.2	5.4
Netherlands	43.8%	18.4%	15.7%	77.8	13.8	8.4
Norway	30.5%	19.5%	17.2%	67.1	30.6	2.3
Poland	38.4%	19.6%	17.5%	75.4	20.3	4.3
Portugal	38.8%	17.5%	16.9%	73.2	20.7	6.1
Romania	37.1%	20.3%	20.9%	78.3	17.3	4.4
Slovakia	37.4%	21.0%	18.9%	77.3	19.2	3.5
Slovenia	36.8%	20.8%	17.2%	74.8	20.8	4.4
Spain	41.3%	19.4%	20.0%	80.7	14.9	4.4
Sweden	34.1%	19.2%	18.3%	71.6	23.0	5.4
United Kingdom	31.4%	19.3%	18.7%	69.3	25.2	5.5

^aRSV-associated hospitalisations in this age group are estimated by also including data from France reported by Demont and colleagues [15]

^bCalculated as a total of the previous three age groups (0-2 months, 3-5 months, 6-11 months)

^cRSV-associated hospitalisations in these two age groups are estimated by also including data from Spain reported by Gil-Prieto and colleagues [14]

397 ^d Includes the UK and excludes Norway

Table 5: Hospitalizations in children under 5 years (all causes and respiratory causes) in EU28 countries and Norway, and % of all

Country	Hospitalizations in children under 5 years, all causes ^a	Hospitalizations in children under 5 years, respiratory causes ^a	RSV-associated hospitalisations in children under 5 years ^b	% of all hospitalisations in children under 5 years due to RSV	% of all respiratory hospitalisations in children under 5 years due to RSV
Austria	na	16,305	3,399 (2,776-4,022)		20.8 (17.0-24.7)
Belgium	na	na	5,807 (4,840-6,774)		
Bulgaria	na	na	3,784 (3,270-4,300)		
Croatia	62,972	8,060	2,046 (1,738-2,356)	3.2 (2.8-3.7)	25.4 (21.6-29.2)
Cyprus	6,839	1,568	477 (405-550)	7.0 (5.9-8.0)	30.4 (25.8-35.1)
Czech Republic	196,900	26,813	5,666 (4,820-6,513)	2.9 (2.4-3.3)	21.1 (18.0-24.3)
Denmark	47,695	7,672	3,073 (2,624-3,518)	6.4 (5.5-7.4)	40.1 (34.2-45.9)
Estonia	na	na	656 (548-762)		
Finland	29,637	6,854	2,945 (2,494-3,400)	9.9 (8.4-11.5)	43.0 (36.4-49.6)
France	1,229,788	127,538	46,027 (40,271-51,781)	3.7 (3.3-4.2)	36.1 (31.6-40.6)
Germany	1,253,873	162,515	34,719 (29,247-40,193)	2.8 (2.3-3.2)	21.4 (18.0-24.7)
Greece	na	na	4,840 (4,115-5,563)		
Hungary	175,698	29,555	4,878 (4,170-5,587)	2.8 (2.4-3.2)	16.5 (14.1-18.9)

hospitalisations and all respiratory hospitalisations that were due to RSV.

	Ireland	53,504	11,637	3,764 (3,255-4,272)	7.0 (6.1-8.0)	32.3 (28.0-36.7)
	Italy	731,993	62,922	25,354 (21,432-29,277)	3.5 (2.9-4.0)	40.3 (34.1-46.5)
	Latvia	na	9,608	1,061 (897-1,222)		11.0 (9.3-12.7)
	Lithuania	78,166	20,663	1,404 (1,172-1,637)	1.8 (1.5-2.1)	6.8 (5.7-7.9)
	Luxembourg	na	777	261 (214-310)		33.6 (27.5-39.9)
	Malta	7,030	642	203 (170-238)	2.9 (2.4-3.4)	31.6 (26.5-37.1)
	Netherlands	na	18,201	4,731 (3,379-6,084)		26.0 (18.6-33.4)
	Norway	84,850	7,251	2,657 (2,182-3,132)	3.1 (2.6-3.7)	36.6 (30.1-43.2)
	Poland	664,693	120,409	17,056 (14,188-19,927)	2.6 (2.1-3.0)	14.2 (11.8-16.5)
	Portugal	98,167	8,069	3,717 (3,069-4,366)	3.8 (3.1-4.4)	46.1 (38.0-54.1)
	Romania	424,339	123,377	8,896 (7,423-10,365)	2.1 (1.7-2.4)	7.2 (6.0-8.4)
	Slovakia	113,651	19,071	2,770 (2,340-3,199)	2.4 (2.1-2.8)	14.5 (12.3-16.8)
	Slovenia	46,511	7,346	1,083 (918-1,248)	2.3 (2.0-2.7)	14.7 (12.5-17.0)
	Spain	na	58,598	17,904 (14,575-21,232)		30.6 (24.9-36.2)
	Sweden	na	10,362	5,351 (4,450-6,251)		51.6 (42.9-60.3)
	United Kingdom	979,392	116,819	39,296 (29,326-49,264)	4.0 (3.0-5.0)	33.6 (25.1-42.2)
r	a: not available					

400 na: not available

401 ^a Data are related to 2015 [11]

402 ^b Estimates calculated in the present manuscript.

403 **References**

- Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden
 estimates of acute lower respiratory infections due to respiratory syncytial virus in
 young children in 2015: a systematic review and modelling study. Lancet 2017; 390:
 946–958.
- Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates
 of acute lower respiratory infections due to respiratory syncytial virus in children
 younger than 5 years in 2019: a systematic analysis. Lancet 2022; 399: 2047–2064.
- 3. Reeves RM, van Wijhe M, Tong S, et al. Respiratory Syncytial Virus-Associated
 Hospital Admissions in Children Younger Than 5 Years in 7 European Countries Using
- 413 Routinely Collected Datasets. J Infect Dis 2020; 222: S599–S605.
- 414 4. Demont C, Petrica N, Bardoulat I, et al. Economic and disease burden of RSV415 associated hospitalisations in young children in France, from 2010 through 2018. BMC
 416 Infect Dis 2021; 21: 730.
- Lee N, Walsh EE, Sander I, et al. Delayed Diagnosis of Respiratory Syncytial Virus
 Infections in Hospitalized Adults: Individual Patient Data, Record Review Analysis and
 Physician Survey in the United States. J Infect Dis 2019; 220: 969–979.
- 420 6. Modjarrad K, Giersing B, Kaslow DC, et al. WHO consultation on Respiratory
 421 Syncytial Virus Vaccine Development Report from a World Health Organization
 422 Meeting held on 23-24 March 2015. Vaccine 2016. p. 190–197.
- Johannesen CK, van Wijhe M, Tong S, et al. Age-Specific Estimates of Respiratory
 Syncytial Virus-Associated Hospitalizations in 6 European Countries: A Time Series
 Analysis. J Infect Dis 2022; 226: S29–S37.
- 426 8. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated
 427 guideline for reporting systematic reviews. BMJ 2021; 372: n71.

428	9.	Simonsen L, Spreeuwenberg P, Lustig R, et al. Global mortality estimates for the 2009
429		Influenza Pandemic from the GLaMOR project: a modeling study. PLoS Med 2013;
430		10: e1001558.

- 431 10. Paget J, Spreeuwenberg P, Charu V, et al. Global mortality associated with seasonal
 432 influenza epidemics: New burden estimates and predictors from the GLaMOR Project.
 433 J Glob Health 2019; 9: 20421.
- 434 11. Eurostat. Hospital discharges and length of stay statistics. Available at:
 435 https://ec.europa.eu/eurostat/statistics-
- 436 explained/index.php?title=Hospital_discharges_and_length_of_stay_statistics&oldid=
- 437 561104#Hospital_discharges_by_sex_and_age [last accessed 10 July 2022]
- 438 12. Reeves RM, Hardelid P, Gilbert R, et al. Estimating the burden of respiratory syncytial
 439 virus (RSV) on respiratory hospital admissions in children less than five years of age
 440 in England, 2007-2012. Influenza Other Respir Viruses 2017; 11: 122–129.
- 441 13. Cromer D, van Hoek AJ, Newall AT, et al. Burden of paediatric respiratory syncytial
 442 virus disease and potential effect of different immunisation strategies: a modelling and
 443 cost-effectiveness analysis for England. Lancet Public Health 2017; 2: e367–e374.
- 444 14. Gil-Prieto R, Gonzalez-Escalada A, Marín-García P, et al. Respiratory Syncytial Virus
 445 Bronchiolitis in Children up to 5 Years of Age in Spain: Epidemiology and
 446 Comorbidities: An Observational Study. Medicine 2015; 94: e831.
- 447 15. Demont C, Bizouard G, Watier L, et al. Excess hospitalisations associated with RSV
 448 among children under 5 years old in France from 2010 to 2018. ESCAIDE Abstract
 449 Book. 2020. 24-27 November. Available at: https://www.escaide.eu/en/general450 information/abstract-books [Last accessed 30 June 2022].

- 451 16. Li Y, Wang X, Broberg EK, et al. Seasonality of respiratory syncytial virus and its
 452 association with meteorological factors in 13 European countries, week 40 2010 to
 453 week 39 2019. Euro Surveill 2022; 27.
- 454 17. Eurostat. Demography, population stock, and balance. Available at:
 455 https://ec.europa.eu/eurostat/web/population-demography/demography-population-
- 456 stock-balance/database [last accessed 10 July 2022]
- 457 18. Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for Prevention of RSV in Healthy
 458 Late-Preterm and Term Infants. N Engl J Med 2022; 386: 837–846.
- 459 19. Karron RA. Preventing respiratory syncytial virus (RSV) disease in children. Science
 460 2021; 372: 686–687.
- 20. Mazur NI, Terstappen J, Baral R, et al. Respiratory syncytial virus prevention within
 reach: the vaccine and monoclonal antibody landscape. Lancet Infect Dis 2023; 23: e2–
 e21.
- 464 21. Teirlinck AC, Broberg EK, Stuwitz Berg A, et al. Recommendations for respiratory
 465 syncytial virus surveillance at the national level. Eur Respir J 2021; 58.
- 22. Bont L, Checchia PA, Fauroux B, et al. Defining the Epidemiology and Burden of
 Severe Respiratory Syncytial Virus Infection Among Infants and Children in Western
 Countries. Infect Dis Ther 2016; 5: 271–298.
- 469 23. Glatman-Freedman A, Kaufman Z, Applbaum Y, et al. Respiratory Syncytial Virus
 470 hospitalisation burden: a nation-wide population-based analysis, 2000-2017. J Infect
 471 2020; 81: 297–303.
- 472 24. Saravanos GL, Sheel M, Homaira N, et al. Respiratory syncytial virus-associated
 473 hospitalisations in Australia, 2006-2015. Med J Aust 2019; 210: 447–453.

474	25. Arriola CS, Kim L, Langley G, et al. Estimated Burden of Community-Onset
475	Respiratory Syncytial Virus-Associated Hospitalizations Among Children Aged <2
476	Years in the United States, 2014-15. J Pediatric Infect Dis Soc 2020; 9: 587–595.
477	26. Paget J, Danielle Iuliano A, Taylor RJ, et al. Estimates of mortality associated with
478	seasonal influenza for the European Union from the GLaMOR project. Vaccine 2022;
479	40: 1361–1369.
480	27. Sanchez-Luna M, Elola FJ, Fernandez-Perez C, et al. Trends in respiratory syncytial
481	virus bronchiolitis hospitalisations in children less than 1 year: 2004-2012. Curr Med
482	Res Opin 2016; 32: 693–698.
483	28. American Lung Association. Learn about respiratory syncytial virus (RSV). 2021.
484	Available at: https://www.lung.org/lung-health-diseases/lung-disease-
485	lookup/rsv/learn-about-rsv. Last accessed [20 Dec 2022].
486	29. Wildenbeest JG, Billard M-N, Zuurbier RP, et al. The burden of respiratory syncytial
487	virus in healthy term-born infants in Europe: a prospective birth cohort study. Lancet
488	Respir Med 2022.
489	30. Green CA, Yeates D, Goldacre A, et al. Admission to hospital for bronchiolitis in
490	England: trends over five decades, geographical variation and association with perinatal
491	characteristics and subsequent asthma. Arch Dis Child 2016; 101: 140-146.
492	31. Suh M, Movva N, Jiang X, et al. Respiratory Syncytial Virus Is the Leading Cause of
493	United States Infant Hospitalizations, 2009-2019: A Study of the National
494	(Nationwide) Inpatient Sample. J Infect Dis 2022; 226: S154–S163.
495	32. Simoes EAF. Environmental and demographic risk factors for respiratory syncytial
496	virus lower respiratory tract disease. J Pediatr 2003; 143: S118–26.
497	33. Fitzpatrick T, McNally JD, Stukel TA, et al. Family and Child Risk Factors for Early-
498	Life RSV Illness. Pediatrics 2021; 147.

499	34. Nenna R, Cutrera R, Frassanito A, et al. Modifiable risk factors associated with
500	bronchiolitis. Ther Adv Respir Dis 2017; 11: 393–401.
501	35. Hardelid P, Verfuerden M, McMenamin J, et al. The contribution of child, family and
502	health service factors to respiratory syncytial virus (RSV) hospital admissions in the
503	first 3 years of life: birth cohort study in Scotland, 2009 to 2015. Euro Surveill 2019;
504	24.
505	36. van Summeren J, Meijer A, Aspelund G, et al. Low levels of respiratory syncytial virus
506	activity in Europe during the 2020/21 season: what can we expect in the coming

- summer and autumn/winter? Euro Surveill 2021; 26.
- 508 37. Sande CJ. Implementation strategies for passive respiratory syncytial virus
 509 immunisation. Lancet Infect Dis 2021; 21: 1200–120

510

Figure 1: Systematic review flow diagram



Figure 2: RSV Hospitalization rates per 1,000 population in different age groups

